Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 12, 2024 | June 14, 2024 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | May 11, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,159 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 6,820 · Balance 70,159 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.30 · Expires 2034-06-12 | Direct | 49,933 |
Reported balance
After 2024-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-12 · Grant · Acquired 49,933 · Balance 49,933 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,500 |
Reported balance
Holding disclosure · report date 2024-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Travere Therapeutics, Inc.
Report date May 11, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,919 |
Reported balance
After 2022-05-11 transaction · row 1
1 source rowRow 1 · 2022-05-11 · Sale · Disposed 2,575 · Balance 146,919 F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Acer Therapeutics Inc.
Report date November 17, 2023 · Filed November 20, 2023
Section 16 reporting ended · disclosed 2023-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-17 transaction · row 1
1 source rowRow 1 · 2023-11-17 · Disposition to issuer · Disposed 483,741 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra. F2: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company. F3: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra.
F2: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company.
F3: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2024 Filed Jun 14, 2024 20:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001127602-24-018708 · form4.xml · derivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 6,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018708 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,159 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 2,500 | $6.40 | $16,000.00 |
DisclosureSEC source: 0001127602-24-016776 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 2,500 Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 17:09 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | Disposition to issuerCommon Stock, $0.0001 par value per share | 483,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-020445 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra. F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company. F3 · kind: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company. F3 · price: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018786 · form4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018786 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,339 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:30 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001209191-23-019300 · doc4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 16:01 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 409,836 | $1.22 | $499,999.92 |
DisclosureSEC source: 0001209191-22-059172 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,741 Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017138 · form4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017138 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,594 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 569 | $9.31 | $5,297.39 |
DisclosureSEC source: 0001127602-22-016409 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,728 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:35 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,575 | $21.92 | $56,456.62 |
DisclosureSEC source: 0001209191-22-028702 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,919 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 301 | $16.61 | $4,999.61 |
DisclosureSEC source: 0001127602-22-007717 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,159 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 16:15 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001209191-22-003708 · doc4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-01-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on January 14, 2023. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 16:02 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 7,984 | $2.04 | $16,287.36 |
DisclosureSEC source: 0001209191-21-069227 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,905 Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 16:02 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 2,016 | $2.15 | $4,334.40 |
DisclosureSEC source: 0001209191-21-069227 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,921 Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 21:15 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 414 | $12.06 | $4,992.84 |
DisclosureSEC source: 0001127602-21-030063 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,858 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:08 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 31,800 | $29.39 | $934,602.00 |
DisclosureSEC source: 0001209191-21-065439 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,494 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.05 to $29.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 19,500 shares previously reported as indirectly held in the name of the Aselage Family Trust. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.23 | $0.00 |
DisclosureSEC source: 0001209191-21-063591 · doc4.xml · derivative · entry 4 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $26.23 | $262,300.00 |
DisclosureSEC source: 0001209191-21-063591 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,794 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $16.23 | $162,300.00 |
DisclosureSEC source: 0001209191-21-063591 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 3,500 | $30.00 | $105,000.00 |
DisclosureSEC source: 0001209191-21-062670 · doc4.xml · nonDerivative · entry 6 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,500 F2 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F1 · ownership.nature: The shares are held in the name of the Aselage Family Trust. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 5,000 | $29.48 | $147,400.00 |
DisclosureSEC source: 0001209191-21-062670 · doc4.xml · nonDerivative · entry 5 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.065 to $29.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: The shares are held in the name of the Aselage Family Trust. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $16.23 | $0.00 |
DisclosureSEC source: 0001209191-21-060035 · doc4.xml · derivative · entry 4 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 60,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 32,000 | $26.26 | $840,320.00 |
DisclosureSEC source: 0001209191-21-060035 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,794 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 28,000 | $26.23 | $734,440.00 |
DisclosureSEC source: 0001209191-21-060035 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,794 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 20:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 60,000 | $16.23 | $973,800.00 |
DisclosureSEC source: 0001209191-21-060035 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:28 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 314 | $15.92 | $4,998.88 |
DisclosureSEC source: 0001127602-21-024772 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,444 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| July 16, 2021 Filed Nov 3, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062670 · doc4.xml · nonDerivative · entry 4 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 28,000 F1 · ownership.nature: The shares are held in the name of the Aselage Family Trust. Read SEC document |
| July 16, 2021 Filed Nov 3, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062670 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,794 Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 634 | $15.77 | $9,998.18 |
DisclosureSEC source: 0001127602-21-018470 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,130 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0001127602-21-018174 · form4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:21 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-21-033851 · doc4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-05-13 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:21 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033851 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,794 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,146 | $19.58 | $42,022.97 |
DisclosureSEC source: 0001209191-21-032312 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,794 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.23 | $0.00 |
DisclosureSEC source: 0001209191-21-027558 · doc4.xml · derivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $26.23 | $262,300.00 |
DisclosureSEC source: 0001209191-21-027558 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,940 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $16.23 | $162,300.00 |
DisclosureSEC source: 0001209191-21-027558 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.23 | $0.00 |
DisclosureSEC source: 0001209191-21-022056 · doc4.xml · derivative · entry 4 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 7,727 | $27.56 | $212,956.12 |
DisclosureSEC source: 0001209191-21-022056 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,940 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.025 to $28.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $27.35 | $273,500.00 |
DisclosureSEC source: 0001209191-21-022056 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,667 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $16.23 | $162,300.00 |
DisclosureSEC source: 0001209191-21-022056 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:47 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 927 | $10.78 | $9,993.06 |
DisclosureSEC source: 0001127602-21-008747 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,496 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| February 21, 2021 Filed Feb 3, 2021 02:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-21-007023 · doc4.xml · derivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 25,000 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 04, 2021 Filed Nov 3, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062670 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,000 F1 · ownership.nature: The shares are held in the name of the Aselage Family Trust. Read SEC document |
| February 04, 2021 Filed Nov 3, 2021 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062670 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,794 Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 02:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 25,000 | $30.75 | $768,750.00 |
DisclosureSEC source: 0001209191-21-007023 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,667 F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 02:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 25,000 | $10.09 | $252,250.00 |
DisclosureSEC source: 0001209191-21-007023 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 16:10 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001209191-21-004261 · doc4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on January 15, 2022. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 01:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 5,549 | $26.02 | $144,384.98 |
DisclosureSEC source: 0001209191-20-063929 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,667 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.